What's Happening?
Moderna has announced its entry into the in vivo CAR-T therapy space, unveiling a lead candidate, mRNA-6007, aimed at treating autoimmune diseases such as systemic lupus erythematosus (SLE). Unlike traditional ex vivo CAR-T therapies, in vivo CAR-T does
not require the extraction and modification of a patient's cells, making it a less invasive and potentially more scalable treatment option. Moderna's approach involves the direct infusion of vector particles that modify T-cells within the body to target and destroy disease-causing cells. This method could transform CAR-T therapy into an off-the-shelf treatment, broadening its applicability across various patient populations.
Why It's Important?
The development of in vivo CAR-T therapies represents a significant advancement in the treatment of autoimmune diseases and potentially other conditions. By eliminating the need for complex cell extraction and modification processes, this approach could make CAR-T therapies more accessible and cost-effective. Additionally, the ability to redose in vivo CAR-T therapies could enhance their efficacy over time. Moderna's expansion into this area underscores the company's commitment to diversifying its treatment modalities beyond mRNA vaccines, potentially leading to new therapeutic options for patients with autoimmune diseases and cancer.
What's Next?
Moderna plans to advance its in vivo CAR-T program with further research and development, including Investigational New Drug (IND) studies to prepare for human testing. The company is also exploring additional applications of this technology in other autoimmune diseases and oncology. As Moderna continues to innovate in this space, the success of its in vivo CAR-T therapies could pave the way for broader adoption of this treatment modality, potentially transforming the landscape of autoimmune and cancer therapies.
